Lightnews — Scholar-powered news

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 1d

In #ALS, analysis of 636 patients (2013–2023) found racial and ethnic disparities in care: Non-Hispanic Black patients had higher tracheostomy rates, and Hispanic patients were less likely to receive riluzole. Survival was similar across groups.

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 1d

In rescue stenting after failed thrombectomy, dual antiplatelet therapy post-procedure improved outcomes and reduced mortality and stent occlusion vs single therapy. Most occlusions occurred within 24 h, underscoring early management importance.

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 1d

In #ParkinsonsDisease, orthostatic hypotension (OH) is a disabling feature linked to poor quality of life and fall risk. This review summarizes pharmacologic and nonpharmacologic strategies for managing OH in PD.

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 8d

Case series: #Levodopa–carbidopa intestinal gel (LCIG) reduced “off” time & dyskinesia in young-onset #MSA-P patients with preserved levodopa response. While ADLs declined with progression, LCIG may offer benefit for selected cases.

journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 8d

🧪 Long-term study of #Cladribine in #MultipleSclerosis shows no loss of humoral immunity after up to 7 years. Patients maintained protective IgG to common pathogens & mounted new responses (e.g. SARS-CoV-2). Supports strong long-term safety profile.

journals.sagepub.com/doi/epdf/10....

2 2

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 8d

New national guidelines for #MyastheniaGravis in Israel standardize diagnosis & treatment. They integrate antibody testing, imaging, thymectomy recommendations, & tailored immunotherapy to improve outcomes & reduce care disparities.

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 15d

Review: immune tolerance in #NMOSD/#MOGAD as an alternative to long-term immunosuppression. Strategies include antigen-specific vaccines/nanoparticles, Treg/Breg cell therapy, and gene editing. Aim: durable remission with fewer systemic effects.

journals.sagepub.com/doi/epdf/10....

1

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 15d

Phase IV MAGNIFY-MS (n=270) in relapsing #MS: cladribine tablets achieved 64% NEDA-3 and 60% NEPAD at 2 years; ARR 0.09 (0.04 Tx-naïve). Biomarkers improved with OCB reduction in 76%, lower KFLC and IgG indices, sustained NfL decline, and no OCT thinning.

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 15d

Cross-sectional study in #MultipleSclerosis (n=80): serum GFAP was higher in progressive MS & correlated with TSPO-PET activity, lesion load, and reduced brain volumes. Findings support sGFAP as a biomarker of astrocyte-driven pathology and MS progression

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 23d

Narrative review on neuropsychiatric disorders in #Parkinsons highlights depression, anxiety, apathy, hallucinations & impulse control disorders as common features. Early detection & tailored multidisciplinary care are essential to improve QoL.

Read here: journals.sagepub.com/doi/epdf/10....

1

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 23d

Prospective study in branch atheromatous disease (#stroke subtype): early intensive therapy with dual antiplatelets + high-intensity statins reduced early neuro deterioration (34.1% vs 48.1%) & improved 90-day outcomes, with no ↑ in major bleeding.

Read: journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 23d

Study in #NMOSD (AQP4-IgG+) & #MOGAD: higher serum GFAP, but not NfL, was linked to lower hippocampal & thalamic volumes and ↑ CSF volume on MRI. Findings support sGFAP as a biomarker of disease activity in AQP4-IgG+NMOSD.

Read here: journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 29d

New online:
READAPT multicenter: #DAPT in mild–moderate ischemic #stroke; anterior vs posterior infarcts (n=932; propensity matched). 90-day recurrent events similar (3.1% vs 2.9%); safety comparable. Posterior infarcts had worse 90-day mRS.

Read here: journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · May 16

📊 In a 13-year real-world study of 3850 MS/NMOSD DMT courses, 24.2% were stopped due to AEs. Just 1.7% were atypical, 3.1% unusually severe—spotlighting rare but impactful safety signals.

🔗 journals.sagepub.com/doi/epdf/10....

#NeuroTwitter #MS #NMOSD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · May 13

🔹 Telitacicept in refractory gMG: In this real-world cohort (n=16), 90% showed symptomatic improvement at 6 months. MG-ADL, QMG, & steroid burden all improved, with no severe AEs reported.
A feasible new add-on for treatment-resistant cases.
🔗 doi.org/10.1177/1756...

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

doi.org

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · May 13

🔹 Zilucoplan in AChR+ gMG: Long-term data from the RAISE-XT OLE study (n=200) showed sustained efficacy through Week 60, with continued MG-ADL improvements & no new safety signals.
A promising maintenance option for patients with mild–severe disease.
🔗 doi.org/10.1177/1756...

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

doi.org

1

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · May 13

Yesterday was #MyalgicEncephalomyelitis & #ChronicIllness Awareness Day
In honour of those living with chronic immunological + neurological conditions, we’re spotlighting new research on generalized myasthenia gravis from Therapeutic Advances in Neurological Disorders 🧵👇

1

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · May 9

📡 In a patient with refractory epilepsy, personalized ANT-DBS settings (125 Hz, 50 μs) suppressed theta/alpha activity more than standard clinical settings (145 Hz, 90 μs). Gamma suppression in-clinic also linked to >50% seizure reduction over 1 year.

doi.org/10.1177/1756...

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · May 9

📉 In 14 MuSK-MG patients, efgartigimod reduced MG-ADL scores from 10.1 to 2.2 by week 4 (p=0.001); 93% maintained benefit >8wks, and 71% reached minimal symptom expression by week 12. Lower steroid needs with CD20/tacrolimus combo.

doi.org/10.1177/1756...

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · May 9

📊 In this US claims study (n=1,568), natalizumab as first-line MS therapy cut relapse rates more than later-line use (ARR: 1.48→0.28 vs 0.92→0.41) and showed greater reductions in hospital stays, ER visits, and outpatient use.

doi.org/10.1177/1756...

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · May 9

🚨 Call for Papers — New Frontiers in Acute Reperfusion Therapies for AIS 🧠

TAN invites submissions on large core infarcts, tandem occlusions, AI in neuroimaging & more. Help shape the future of stroke care.

🗓️ Deadline: Sept 19, 2025

🔗 journals.sagepub.com/topic/collec...

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · Apr 22

🚨 A meta-analysis of 26 trials (160k+ participants) suggests GLP-1 drugs (like semaglutide in Ozempic/Wegovy) may significantly reduce dementia risk—potentially via anti-inflammatory effects, not just glucose control.

🧠 More via @newscientist: www.newscientist.com/article/2475...

Drugs like Ozempic and Wegovy could significantly cut dementia risk

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that they really could protect against dementia

www.newscientist.com

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · Apr 22

🧪 In early Parkinson’s disease, higher baseline plasma NfL levels were linked to both persistent and new-onset fatigue at 2-year follow-up. NfL may serve as a predictive biomarker for fatigue subtype conversion in PD.

Read here: journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · Apr 16

In RRMS, 6 months of dimethyl fumarate therapy significantly altered gut microbiota composition, increasing Firmicutes families and reducing Bacteroidetes and Proteobacteria. Pre-treatment profiles predicted both 1-year disease activity and adverse events

journals.sagepub.com/doi/epdf/10....

2 2

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · Apr 16

Fatigue (HR 1.98, p=0.024) and poor sleep (HR 2.19, p=0.004) at epilepsy diagnosis predict ASM resistance.
Depression severity mediated 18.5% (fatigue) and 23.7% (sleep) of the effect.

🔗 journals.sagepub.com/doi/epdf/10....

1 2